ClinicalTrials.gg
RecruitingNCT05931939Updated Apr 16, 2024

Laparoscopic Ileal Interposition and Weight Regain

An interventional study of Ileal Interposition and Traditional surgical technique in Obesity, sponsored by Rio de Janeiro State University. Recruiting at 1 site in Brazil. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Rio de Janeiro State University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The investigators will study the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones

Read the detailed description

This prospective, controlled, randomized intervention study will investigate the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, health-related quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones. The participants will also be assessed for alcohol abuse, depressive symptoms, level of physical activity, eating disorder symptoms, and dumping syndrome.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 30 is below the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Rio de Janeiro State University is the lead sponsor of 62 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients submitted to initial laparoscopic after initial Roux-en-Y gastric bypass for at least 3 years
  • Loss of excess weight between 60 to 80%
  • Rate of weight regain ≥60%
  • ≥ 40 kg/m2 or ≥ 35 kg/m2, with at least 2 comorbidities associated with obesity
  • Present a previous evaluation by the multidisciplinary team with a favorable opinion of the revision surgery.

Exclusion criteria

Exclusion Criteria:

  • Active chemical dependency on alcohol and/or illicit drugs
  • Severe psychotic or depressive disorder or history of suicide attempts in the last 12 months
  • Eating behavior disorder (uncontrolled)
  • Secondary causes of obesity
  • Pregnancy
  • Severe organ failure
  • Active neoplastic
  • Infectious or inflammatory disease
  • Severe coagulopathy
  • High anesthetic-surgical risk
  • Intellectual inability
  • Lack of preoperative follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ileal Interposition

    Interposition ileal surgery group Procedure/Surgery: Bariatric surgery

    Procedure: Ileal Interposition

  • Active comparator
    Traditional surgical technique

    Conventional revisional surgery group Procedure/Surgery: Bariatric surgery

    Procedure: Traditional surgical technique

Interventions

  • ProcedureIleal Interposition

    Bariatric surgery by laparoscopic Ileal Interposition

  • ProcedureTraditional surgical technique

    Bariatric surgery by laparoscopic traditional technique

06

What researchers measure

Primary outcomes

  1. Changes of weight loss of participants after Ileal interposition surgery as measured by weight in kilograms

    Weight loss will be obtained as the difference between preoperative weight and minimum postoperative weight in kilograms

    Time frame: Change from baseline and after 6 months post-surgery

  2. Changes of Health-related quality of life of participants after Ileal interposition surgery as reported by 36-Item Short-Form Health Survey questionnaire

    Health-related quality of life will be assessed using the 36-Item Short-Form Health Survey questionnaire

    Time frame: Change from Baseline and after 6 months post-surgery

Secondary outcomes

  1. Changes of weight loss of participants after Ileal interposition surgery as measured by weight in kilograms

    Weight loss will be obtained as the difference between preoperative weight and minimum

    Time frame: Change from baseline and after 3, 6, and 12 months post-surgery

  2. Change of body composition of participants after Ileal interposition surgery as measured by lean and fat mass in kilograms

    Body composition will be assessed through dual X-ray absorptiometry (DXA)

    Time frame: Change from baseline and after 6 and 12 months post-surgery

  3. Change of metabolic profile of participants after Ileal interposition surgery as assessed by serum levels of glucose and insulin

    Blood sample collection will include serum levels of glucose and insulin

    Time frame: Change from baseline and after 6 and 12 months post-surgery

  4. Change of inflammatory biomarkers and incretin hormones of participants after Ileal interposition surgery as assessed by serum levels of tumor necrosis factor-alpha, interleukin-6, ghrelin, and glucagon-like peptide-1.

    Blood sample collection will include serum levels of tumor necrosis factor-alpha, interleukin-6, ghrelin, and glucagon-like peptide-1.

    Time frame: Change from baseline and after 6 months post-surgery

  5. Changes in alcohol abuse of participants after Ileal interposition surgery as reported by Alcohol Use Disorders Identification Test

    Alcohol abuse will be assessed using the Alcohol Use Disorders Identification Test

    Time frame: Change from baseline and after 6 and 12 months post-surgery

  6. Changes in depressive symptoms of participants after Ileal interposition surgery as reported by Beck Depression Inventory

    Depressive symptoms will be assessed using the Beck Depression Inventory questionnaire

    Time frame: Change from baseline and after 6 and 12 months post-surgery

  7. Changes in the level of physical activity of participants after Ileal interposition surgery as reported by the International Physical Activity Questionnaire

    Levels of physical activity will be assessed using the International Physical Activity Questionnaire

    Time frame: Change from baseline and after 6 and 12 months post-surgery

  8. Changes in the eating disorder symptoms of participants after Ileal interposition surgery as reported by the Eating Disorder Examination Questionnaire

    Eating disorder symptoms will be assessed using the Eating Disorder Examination Questionnaire

    Time frame: Change from baseline and after 6 and 12 months post-surgery

07

Study locations

1 of 1 sites recruiting
  • State University of Rio de Janeiro
    Rio de Janeiro, Brazil
    Recruiting
    • Luiz Guilherme Kraemer-Aguiar, PhD · Contact55212868-8212
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05931939
Lead sponsor
Rio de Janeiro State University
Responsible party
Luiz Guilherme Kraemer-Aguiar, MD (Principal Investigator, Rio de Janeiro State University) — Principal investigator
First posted
Jul 6, 2023
Start date
Dec 1, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Apr 16, 2024

Study contacts

Luiz Guilherme G Kraemer-Aguiar, PhD
Contact
lgkraemeraguiar@gmail.com
+55 21 23340703
Karynne Grutter Lopes, PhD
Contact
kjgolrj@gmail.com
Luiz Guilherme Kraemer-Aguiar, PhD
principal investigator · State University of Rio de Janeiro
Paulo Roberto G Falcão Leal, MD
principal investigator · State University of Rio de Janeiro
Karynne G Grutter Lopes, PhD
principal investigator · State University of Rio de Janeiro

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion